Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
(Posted: 06/19/2009, Updated: 10/01/2010) - Patients with advanced gastric cancer who received standard chemotherapy plus trastuzumab (Herceptin®) survived several months longer than those who received chemotherapy alone, according to findings presented at the 2009 ASCO meeting in Orlando.
Addition of immunotherapy boosts pediatric cancer survival:
(Posted: 09/29/2010) - Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years. The percentage rose from 46 percent for children receiving a standard therapy to 66 percent for children receiving immunotherapy plus standard therapy, according to the study in the Sept. 30, 2010, New England Journal of Medicine.
Reducing Treatment Intensity Doesn't Compromise Results in Early-Stage Hodgkin Lymphoma
(Posted: 09/27/2010) - Reducing the dose of chemotherapy and radiotherapy did not compromise treatment efficacy in patients with early-stage, low-risk Hodgkin lymphoma but led to fewer side effects, according to a study published August 12, 2010, in the New England Journal of Medicine.
Targeted Drug for Melanoma Shows Promise in Early Clinical Testing
(Posted: 09/24/2010) - The vast majority of patients with advanced melanoma who received an experimental targeted drug called PLX4032 responded to the treatment in a phase I clinical trial, researchers reported in the August 26, 2010, New England Journal of Medicine.
Drug Protects Heart in Children Receiving Common Chemotherapy
(Posted: 09/24/2010) - The drug dexrazoxane, which can protect heart tissue from the oxidative damage caused by doxorubicin and other anthracycline drugs, reduced long-term heart damage in children undergoing treatment for high-risk acute lymphoblastic leukemia (ALL) but did not affect treatment efficacy, according to a study published September 15, 2010, in Lancet Oncology.